Vaccination strategies for mitigation of MERS-CoV outbreaks.
作者信息
Bosaeed Mohammad, Alharbi Naif Khalaf
机构信息
Department of Medicine, King Abdulaziz Medical City, Riyadh 11426, Saudi Arabia; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Gulf Center for Disease Prevention and Control, Riyadh, Saudi Arabia.
出版信息
Lancet Glob Health. 2023 May;11(5):e644-e645. doi: 10.1016/S2214-109X(23)00164-X.
Abstract
摘要
相似文献
1
Vaccination strategies for mitigation of MERS-CoV outbreaks.
Lancet Glob Health. 2023 May;11(5):e644-e645. doi: 10.1016/S2214-109X(23)00164-X.
2
Evaluating the potential impact of targeted vaccination strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting.
Theor Biol Med Model. 2019 Oct 7;16(1):16. doi: 10.1186/s12976-019-0112-6.
3
Middle East Respiratory Syndrome Corona Virus (MERS CoV): The next steps.
J Public Health Policy. 2015 Aug;36(3):318-23. doi: 10.1057/jphp.2015.9. Epub 2015 Mar 26.
4
Research needed to prevent MERS coronavirus outbreaks.
Lancet. 2017 Apr 15;389(10078):1502. doi: 10.1016/S0140-6736(17)30998-4.
5
Case characteristics among Middle East respiratory syndrome coronavirus outbreak and non-outbreak cases in Saudi Arabia from 2012 to 2015.
BMJ Open. 2017 Jan 12;7(1):e011865. doi: 10.1136/bmjopen-2016-011865.
6
MERS: What is the current situation in Saudi Arabia?
J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay065.
7
Is Crisis and Emergency Risk Communication as Effective as Vaccination for Preventing Virus Diffusion? Measuring the Impacts of Failure in CERC with MERS-CoV Outbreak in South Korea.
Risk Anal. 2022 Jul;42(7):1504-1523. doi: 10.1111/risa.13842. Epub 2021 Oct 15.
8
A Comparative Analysis of Factors Influencing Two Outbreaks of Middle Eastern Respiratory Syndrome (MERS) in Saudi Arabia and South Korea.
Viruses. 2019 Dec 3;11(12):1119. doi: 10.3390/v11121119.
9
Comparative Analysis of Eleven Healthcare-Associated Outbreaks of Middle East Respiratory Syndrome Coronavirus (Mers-Cov) from 2015 to 2017.
Sci Rep. 2019 May 14;9(1):7385. doi: 10.1038/s41598-019-43586-9.
10
Exportations of Symptomatic Cases of MERS-CoV Infection to Countries outside the Middle East.
Emerg Infect Dis. 2016 Apr;22(4):723-5. doi: 10.3201/eid2204.150976.
引用本文的文献
1
Mucosal immunity in upper and lower respiratory tract to MERS-CoV.
Front Immunol. 2024 Aug 30;15:1358885. doi: 10.3389/fimmu.2024.1358885. eCollection 2024.
2
Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2351664. doi: 10.1080/21645515.2024.2351664. Epub 2024 May 17.
本文引用的文献
1
Impact of proactive and reactive vaccination strategies for health-care workers against MERS-CoV: a mathematical modelling study.
Lancet Glob Health. 2023 May;11(5):e759-e769. doi: 10.1016/S2214-109X(23)00117-1.
2
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
Lancet Microbe. 2022 Jan;3(1):e11-e20. doi: 10.1016/S2666-5247(21)00193-2. Epub 2021 Nov 3.
3
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
4
High Rate of Circulating MERS-CoV in Dromedary Camels at Slaughterhouses in Riyadh, 2019.
Viruses. 2020 Oct 27;12(11):1215. doi: 10.3390/v12111215.
5
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
Vaccine. 2021 May 21;39(22):3067-3080. doi: 10.1016/j.vaccine.2020.08.050. Epub 2020 Oct 17.
6
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Lancet Infect Dis. 2020 Jul;20(7):827-838. doi: 10.1016/S1473-3099(20)30248-6. Epub 2020 Apr 21.
7
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24.
8
MERS coronavirus: diagnostics, epidemiology and transmission.
Virol J. 2015 Dec 22;12:222. doi: 10.1186/s12985-015-0439-5.
9
Prime-boost vectored malaria vaccines: progress and prospects.
Hum Vaccin. 2010 Jan;6(1):78-83. doi: 10.4161/hv.6.1.10116. Epub 2010 Jan 18.
Zotero 插件